Joshua “Scotch” McClure, the founder and CEO of Maxwell Biosciences, is a notable figure in the field of longevity and infectious disease. His company is making headlines with its development of Claromers™, a proprietary version of peptoids derived from the naturally occurring antimicrobial peptide LL-37. This innovation aims to combat infections that could potentially lead to an extension of human healthspan and lifespan.

The Vision Behind Maxwell Biosciences

McClure's enthusiasm for longevity science stems from a childhood fascination with genetics. His transition into the field was catalyzed by personal family health crises involving antibiotic-resistant infections. This experience entrenched his conviction that infectious diseases are a significant factor driving the aging process.

McClure posits that many individuals harbor chronic subacute infections, such as the Epstein-Barr virus, without realizing they are impacting their overall health and energy levels. He highlights that these infections can subtly undermine a person's vitality, manifesting as fatigue or diminished cognitive function.

Scientific Foundations and Innovations

As a data scientist with a keen interest in biophysics, McClure’s approach integrates computational modeling and biological research. His major goal is to develop a mass-scale, accessible medicinal solution that ensures immunity against common and deadly infections.

“Infectious disease is the primary driver of aging. It is the primary disruptor of homeostasis.” – Joshua McClure

Understanding LL-37 and the Role of Claromers™

LL-37 is an essential component of the human innate immune system, functioning as a broad-spectrum antimicrobial agent. However, its potential is hampered by instability, as McClure notes: “It’s like wet toilet paper – it falls apart very quickly.” To address this, McClure's laboratory worked on stabilizing the peptide, giving rise to their innovative Claromers™.

Claromers™: Mechanism of Action

The mechanism of action for Claromers™ involves targeting negatively charged phospholipids on the membranes of pathogens. This approach enables the Claromers™ to selectively destroy harmful microorganisms while preserving beneficial gut flora. This selectivity is critical, as preserving the commensal microbiome is essential for maintaining overall health.

Preclinical Studies and Future Applications

Preliminary studies using non-human primates showed promising results, indicating that Claromers™ could effectively combat multi-drug-resistant infections without toxic effects on human cells or the microbiome.

According to McClure, the first FDA-approved application of their drug could potentially “lengthen healthspan immediately,” as infectious diseases are tackled head-on.

Study Type Pathogen Targeted Outcome
Non-Human Primate Study MRSA No observed toxicity and effective pathogen eradication.
Virology Study Coronaviruses, Influenza Broad-spectrum effectiveness noted.

Broader Implications for Public Health

McClure's vision extends beyond personal health. He has engaged with governments and military organizations to improve defense against infectious diseases on a larger scale. Collaborations with countries such as India focus on tackling antibiotic-resistant infections that plague rural areas, which face challenges in accessing diagnostics and effective treatments.

Potential Impact of the Technology

  • Reducing Infection-Related Deaths: Addressing the root causes of infections can lead to fewer complications in elderly populations.
  • Enhancing Recovery: Individuals recovering from illnesses like hip fractures may benefit significantly due to improved immune response.
  • Increasing Lifespan: As infections are managed effectively, the overall health and longevity of populations could be enhanced.

The Future of Infectious Disease and Aging

McClure firmly believes that resolving issues associated with infectious diseases could potentially grant individuals an additional 20 to 40 years of healthspan. This assertion connects directly to how society chooses to confront the bacteria and viruses that cohabitate with humanity.

“This technology is going to eradicate infectious disease and more.” – Joshua McClure

To learn more about McClure and Maxwell Biosciences, visit their website at Maxwell Biosciences.

Conclusion

Joshua “Scotch” McClure exemplifies the intersection of innovation and necessity in the fight against aging and illness. His work could ultimately redefine how we approach health and longevity, positioning infectious disease management as a cornerstone of future medical interventions.

References

[1] McClure, J. (2025). Interview on the role of infectious diseases in aging. Lifespan Research Institute.

[2] Maxwell Biosciences. (2025). Research and Product Development.

[3] Journal of Infectious Diseases. (2025). The impact of antimicrobial peptides on public health.